Literature DB >> 9858029

Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia.

K Ohara1, M Nagai, K Tani, Y Nakamura, A Ino, K Ohara1.   

Abstract

Several studies showed the density of D2 receptors was elevated in postmortem brains from schizophrenics. Genes which operate at the level of gene activation may be associated with the pathogenesis of schizophrenia. Arinami et al. [(1997) Human Molecular Genetics 6, 577-582] found a polymorphism in the 5'-flanking region of the D2 receptor gene designated as -141C Ins/Del. The promoter activity by luciferase assay of a plasmid containing the -141C Ins allele was higher than in the one containing the -141C Del allele. In addition, the -141C Ins allele frequency was significantly higher in schizophrenics than in control subjects. We replicated the -141C Ins/Del polymorphism in 170 schizophrenics and 121 healthy control subjects. The number of schizophrenics with the -141C Ins/Ins genotype was significantly higher than that of control subjects (P = 0.038). The frequency of the -141C Ins allele was significantly increased in the schizophrenics compared with the control subjects (P = 0.042). The mean age of onset for the patients with -141C Ins/Del was significantly lower than that for the patients with -141C Ins/Ins (P = 0.029). There was no association between the genotype and either positive symptoms or the response to antipsychotic medication. Our results suggest that the -141C Ins/Del polymorphism may affect the susceptibility to schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9858029     DOI: 10.1016/s0165-1781(98)00092-4

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  14 in total

Review 1.  Genetic analyses of schizophrenia.

Authors:  C N Pato; K M Schindler; M T Pato
Journal:  Curr Psychiatry Rep       Date:  2000-04       Impact factor: 5.285

Review 2.  Molecular genetics of schizophrenia: a critical review.

Authors:  Neeraj Berry; Vaidehi Jobanputra; Hemraj Pal
Journal:  J Psychiatry Neurosci       Date:  2003-11       Impact factor: 6.186

3.  PharmGKB summary: dopamine receptor D2.

Authors:  Huaiyu Mi; Paul D Thomas; Huijun Z Ring; Ruhong Jiang; Katrin Sangkuhl; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-06       Impact factor: 2.089

4.  Molecular epidemiology of major depressive disorder.

Authors:  Chikako Kiyohara; Kouichi Yoshimasu
Journal:  Environ Health Prev Med       Date:  2009-01-20       Impact factor: 3.674

Review 5.  Pharmacogenetics as a tool in the therapy of schizophrenia.

Authors:  Bob Wilffert; Rianne Zaal; Jacobus R B J Brouwers
Journal:  Pharm World Sci       Date:  2005-02

6.  Is the dopamine D3 receptor mRNA on blood lymphocytes help to for identification and subtyping of schizophrenia?

Authors:  M Urhan-Kucuk; M E Erdal; M E Ozen; S Kul; H Herken
Journal:  Mol Biol Rep       Date:  2010-11-26       Impact factor: 2.316

7.  Updated findings of the association and functional studies of DRD2/ANKK1 variants with addictions.

Authors:  Yunlong Ma; Wenji Yuan; Xianzhong Jiang; Wen-Yan Cui; Ming D Li
Journal:  Mol Neurobiol       Date:  2014-08-20       Impact factor: 5.590

8.  Dopamine D2 receptor gene -141C Insertion/Deletion polymorphism in Turkish schizophrenic patients.

Authors:  Hulyam Kurt; Miris Dikmen; Ayşe Basaran; Cinar Yenilmez; Figen Ozdemir; Irfan Degirmenci; Hasan Veysi Gunes; Meral Urhan Kucuk; Fezan Mutlu
Journal:  Mol Biol Rep       Date:  2010-07-28       Impact factor: 2.316

Review 9.  G protein-coupled receptors in major psychiatric disorders.

Authors:  Lisa A Catapano; Husseini K Manji
Journal:  Biochim Biophys Acta       Date:  2006-10-03

10.  Identification of the mRNA expression status of the dopamine D2 receptor and dopamine transporter in peripheral blood lymphocytes of schizophrenia patients.

Authors:  Liang Liu; Guozhen Yuan; Zaohuo Cheng; Guofu Zhang; Xiaowei Liu; Huifang Zhang
Journal:  PLoS One       Date:  2013-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.